CCA
IMNM icon

Cygnus Capital Advisors’s Immunome IMNM Stock Holding History

Cygnus Capital Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150 Sell
6,880
-1,105
-14% -$24.6K 0.1% 55
2025
Q4 		$172 Buy
+7,985
New +$140K 0.13% 52

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Cygnus Capital Advisors's IMNM Position: Q1 2026 in Review

Cygnus Capital Advisors reduced its Immunome (IMNM) stake by 14% in Q1 2026, selling an estimated $24.6K and leaving 6,880 shares worth $150. The position accounts for 0.1% of the portfolio, ranked #55.

Cygnus Capital Advisors first reported a position in IMNM in Q4 2025 and has held it in 2 quarters since. The position peaked at $172 in Q4 2025. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Cygnus Capital Advisors held 6,880 shares of Immunome worth $150 as of Q1 2026.
  • Cygnus Capital Advisors sold 1,105 Immunome shares in Q1 2026, an estimated $24.6K.
  • Immunome made up 0.1% of Cygnus Capital Advisors's portfolio in Q1 2026, its #55 holding.
  • Cygnus Capital Advisors first reported a position in Immunome in Q4 2025 and has held it in 2 quarters since.
  • Cygnus Capital Advisors's Immunome position peaked at $172 in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.